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ABSTRACT 
Objective: The present work was designed to evaluate the antidiabetic effect of Nepeta hindostana methanolic extract in streptozotocin-induced 
diabetes in rats. 
Methods: Wistar rats were divided into different groups and glibenclamide (2.5 mg/kg), and Nepeta hindostana methanolic extract (100, 200 and 
400 mg/kg) treatments were given orally, for 28 d. Change in body weight, glucose level, lipid profile, total cholesterol, and triglyceride level in 
tissue homogenates, total hemoglobin, and HbA1C and pancreas microscopy of different groups were evaluated. 
Results: Nepeta hindostana methanolic extract 200 and 400 mg/kg dose group have a significant change in weight as compared to diabetic control. 
All the extract treated groups showed a significant reduction in glucose level on 14
1* 
Department of Pharmaceutical Sciences, Maharishi Markandeshwar University, Mullana, Ambala, Haryana 133207, India 
Email: randhirsingh.dahiya@gmail.com  
th and 28th
Keywords: Nepeta hindostana, Streptozotocin, Antidiabetic 
 day as compared to diabetic control. The level of serum 
total cholesterol and triglyceride level were significantly reduced, and HDL level significantly increased in 400 mg/kg groups after 28 d treatment. 
However, a significant increase in Hb concentration was observed in diabetic rats treated with 200 and 400 mg/kg, when compared to diabetic 
control. The microscopy of the pancreas showed both glibenclamide and 400 mg/kg extract does appear to regulate diabetes at the cellular level 
resulting in restoration of near normal architecture pancreatic islets of langerhans and hepatocytes. 
Conclusion: It can be concluded that Nepeta hindostana methanolic extract exhibit significant antidiabetic activity against streptozotocin-induced 
diabetes model.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Diabetes mellitus (DM) is a wide-reaching health problem due to its 
high mortality rates and the prevalence of its occurrence is 
increasing at a scary rate. In addition, indicated a growing burden of 
diabetes particularly in developing countries [1]. It was estimated to 
6.4% affecting 285 million adults by the world prevalence of 
diabetes in 2010 among adults. It is expected to increase to 7.7% 
and affecting 438 million adults by 2030 [2]. Diabetes mellitus often 
referred to simply as diabetes is a syndrome of disordered 
metabolism, usually due to a combination of hereditary, and 
environmental causes, resulting in abnormally high blood sugar 
levels (hyperglycemia) [3]. Apart from these interconnected factors, 
the main reason for the occurrence of diabetes is high blood glucose 
level in the body [4]. A consequence of a disturbance in blood-
glucose level is due to improper metabolism of carbohydrate, fat, 
and protein. If an imbalance in the blood glucose level can’t control 
for a long time, then it leads to multiple complications i.e. 
cardiovascular diseases, nephropathy, retinopathy, and neuropathy 
[5]. Currently available anti-diabetic medications have expected for 
their efficacies in lowering blood glucose which leads to lowering 
rates of secondary complications of this disease and to increase 
pharmacological responses [6]. There are a number of complications 
are involved, when patients exposed to an available modern system 
of treatment. To overcome or avoid these complications associated 
with the modern system of medicine accordingly, so, there is a need 
for an alternative therapy i.e. traditional herbal system of medicine. 
To increase, the therapeutic outcomes in the diseased conditions at 
equally effective besides being at an economical price, ethno 
medicine can be considered as “Model of Therapy” for diabetes 
mellitus. It is considered that in the scientific literature, a large 
number of medicinal plants, Functional food and their secondary 
metabolites are considered to be a potential source to control DM 
[7]. Natural products/dietary phytochemical have aroused 
considerable interest in recent years as potential therapeutic agents 
to counteract diabetes. Out of a large number of plants in the 
Ayurveda system of medicine, Nepeta hindostana was selected for 
the present study. 
Nepeta hindostana (Roth) Haines (Family: Lamiaceae) is an 
important medicinal plant of indo-pakistan subcontinent and 
commonly known as “Badrang-e-Boya. It is medium size velvety 
annual herb, 15-40 cm high, branched from base. Leaves are 1.3-5.0 
by 1.3-8.0 cm, broadly ovate, obtuse, crenate-serrate, green or hoary, 
petioles 8-12 mm long. Flower are pedicellate, 6 mm, blue or purple, 
minutely dotted; one-sided stalked, and branched, clusters at the 
interval. Fresh herb has a strong smell like that of mint [8, 9]. It’s 
found roadside and near streams in Europe, Asia (in the Himalayas) 
and in other hilly areas introduced in India. Flowering time of 
Nepeta hindostana is from spring to summer with blue-purple colour 
flowers [10, 11]. 
Traditionally, the plant is used as carminative, stimulant, tonic, 
diaphoretic, emmenagogue, antispasmodic, aphrodisiac, hysteria, 
chlorosis, colic, amenorrhea and toothache [12]. A number of 
pharmacological activities like cardio protective [13, 14], asthma 
[12], hypocholesterolemic [15], hypotensive [16], antiphlogistic 
[17], antiplasmodial [18], antipyretic [19, 20], anti-inflammatory 
[21], CNS depressant and sedative activities [21], antifungal [22] has 
been reported for Nepeta hindostana. The cardio protective effect of 
the plant was reported due to the presence of terpenoid and 
flavonoids [13] but antidiabetic activity was not reported yet for 
Nepeta hindostana. So, the present study was designed to investigate 
the antidiabetic activity of aqueous extract of Nepeta hindostana 
whole herb in streptozotocin-induced diabetes in rats. 
MATERIALS AND METHODS 
Chemical used 
Glibenclamide (beta drugs), streptozotocin (sigma-aldrich), 
methanol (nice chemicals) and erba diagnostic kits were used for 
biochemical estimation. 
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The fresh whole herb of Nepeta hindostana was collected on April 
2013 from the Ch. Devi Lal Rudraksh Vatika Herbal Nature Park, 
Yamunanagar, Haryana and authenticated by Dr. Shiddamallayya N., 
National Ayurveda Dietetics Research Institute, Banglore, India with 
specimen number RRCBI-MUS-125.  
Preparation of methanolic extracts of Nepeta hindostana whole 
herb (NHME) 
The whole herb of Nepeta hindostana was washed in water and 
shade dried. The dried herb was grinded into coarse powder. Then, 
plant material was packed into soxhlet, and extraction was carried 
using methanol. Soxhlation was carried for 72 h and the extract was 
concentrated using rotary vacuum evaporator at 40 °Cand dried. 
The extract was stored in a refrigerator at 4 °Cthroughout the 
duration of the study. Percentage yield of NHME was determined 
using the formula:  
% Yield = (weight of extract/weight of plant material) * 100 
Animals 
Wistar rats (both sex) weighing 130-170g were used in the study and 
experimental protocol was duly approved by Institutional Animal 
Ethics Committee (MMCP/IAEC/13/36). Animals were kept as per the 
guidelines of committee for the purpose of control and supervision of 
experiments on animals (CPCSEA) in MM College of Pharmacy, 
Ambala, India. Animals were fed normal chow diet and ad libitum 
under controlled environmental condition of temperature (24-28 °C), 
relative humidity 60-70% and natural light/dark cycle (12:12).  
Induction of diabetes with streptozotocin [23-25] 
Diabetes was induced by intraperitoneal injection of streptozotocin 
(55 mg/kg) dissolved in 0.1 M cold sodium citrate buffer (pH 4.5) in 
overnight fasting rats. The control rats received vehicle alone, and 
animals were allowed to drink 5% glucose solution overnight to 
overcome the drug-induced hypoglycemia. After 1 w time, the rats 
with moderate diabetes having glycosuria and hyperglycemia (blood 
glucose range of above 250 mg/dl) were considered as diabetic rats 
and used for the experiment.  
The rats were divided into groups of 6 animals in each group as 
given below.  
Group 1: Control rats, received saline 10 ml/kg 
Group 2: Diabetic control (Streptozotocin) rats, received 55 mg/kg, i. p. 
Group 3: Glibenclamide rats, received 2.5 mg/kg, p. o. 
Group 4: NHME rats, received 100 mg/kg, p. o. 
Group 5: NHME rats, received 200 mg/kg, p. o. 
Group 6: NHME rats, received 400 mg/kg, p. o. 
Glibenclamide (2.5 mg/kg) used as standard drug. The plant extracts 
and standard drug were suspended in 0.9% NaCl in warm water as 
vehicle solution and administered orally for 28 d. 
Changes in body weight 
The changes in the body weight were recorded at every week and % 
changes in body weight were calculated using the formula:  
% change in weight = (final weight initial weight)/initial weight * 100  
Biochemical estimations 
The fasting blood glucose was measured on 0th, 14th, and 28th
VLDL = triglycerides/5 
Estimation of total hemoglobin and HbA1C  
At the end of the study, estimation of total hemoglobin and HbA1C 
were analyzed from blood samples. Total hemoglobin was analyzed 
using Sahli’s haemometer and HbA1C was estimated via laboratory 
method (ion exchange resin method) using semi auto analyzer. 
Estimation of lipids from liver homogenates 
The rats were fasted and sacrificed by cervical decapitation. For 
lipids analysis in tissue, a portion of liver tissue was dissected out, 
washed with ice cold saline immediately and kept at 4 
 days 
with GOD-POD estimation kit. After 28 d treatment, blood samples 
withdrawn from the retro-orbital plexus and serum was separated 
by centrifugation at a speed of 3000 rpm for 10 min and lipid levels 
were estimated. The triglycerides, total cholesterol (CHOD-PAP 
method) and HDL (CHOD-PAP Method) with erba enzymatic kits 
were measured. The levels of LDL and VLDL were calculated using 
Friedewald equation as follows:  
LDL = total cholesterol-HDL-(triglycerides/5) 
oC. The liver 
tissue was homogenized in 0.1M tris-HCl (pH 7.4) and the 
supernatant was quantified for total cholesterol and triglyceride 
with enzymatic kits. 
Histopathological studies 
A portion of pancreatic tissue was dissected out and fixed in 10% 
formalin solution and histopathological studies were carried out. 
Statistical analysis 
Statistical analysis was performed using Dunnett's multiple 
comparisons test. Values are expressed as mean±SEM and p<0.05 
was considered statistically significant.  
RESULTS 
Changes in the body weight of animals in streptozotocin-
induced diabetes  
The antidiabetic effect of NHME was evaluated via streptozotocin-
induced diabetes in rat’s 28 d studies. The weight of rats was 
weighed weekly i.e. on 0th, 7th, 14th, 21st and 28th
There was a persistent increase in blood sugar level of 
streptozotocin-induced diabetic control group i.e. from 268.8 to 
317.9 mg/dl. Compared to normal control group, NHME 400 mg/kg 
treated group showed gradual and moderate antihyperglycemic 
effect i. e from 269.5 to 116.4 mg/dl (fig. 2). 
  
Table 1: Effect of NHME on % change in weight in streptozotocin-induced diabetes 
 day. Normal control 
animals had normal growth in their body weight, but diabetic rats 
showed a significant reduction in body weight during the 28 d 
treatment (fig. 1). All animals treated with streptozotocin in the 
diabetic control group showed a significant change in body weight 
(g) (from 158.8 to 136.5) which was persistently observed till the 
end of the study period. NHME 200 and 400 mg/kg group have a 
significant change in weight as compared to diabetic control (table 
1). In NHME 200 mg/kg group, animals were showed maximum 
weight change after 28 d treatment (from 165.2 to 187.8). 
Effect of NHME on glucose level in streptozotocin induced 
diabetes  
Groups/treatment % change in weight 
Normal Control 11.3% 
Streptozotocin control -14.1% 
Glibenclamide 15.95% 
NHME 100 mg/kg -1.66% 
NHME 200 mg/kg 13.6% 
NHME 400 mg/kg 7.04% 
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Fig. 1: Changes in the body weight of animals in streptozotocin-
induced diabetes. Values are represented as mean±SEM, n=6 
 
 
Fig. 2: Effect of NHME on glucose level in streptozotocin induced 
diabetes 
Values are represented as mean±SEM, n=6. Statistically analysis 
was done with Dunnett’s Multiple Comparison Test and p<0.05 
was considered to be statistically significant; b = vs diabetic 
control; c = vs 100 mg/kg dose; p<0.05 = *; p<0.01= ^; p<0.001= # 
 
Effect of NHME on lipids level in streptozotocin-induced diabetes  
The level of serum TC, TG, LDL and VLDL cholesterol was 
significantly increased, whereas the level of HDL cholesterol was 
significantly reduced in untreated diabetic rats as compared to 
normal control. After treatment of NHME 400 mg/kg, the level of 
serum total cholesterol and VLDL level were significantly reduced. 
The level of TG was found statistically significantly in NHME 200 mg/kg 
and 400 mg/kg groups. Whereas, the level of serum HDL cholesterol was 
significantly increased in NHME all dose groups (fig. 3). 
 
 
Fig. 3: Effect of NHME on lipids level in streptozotocin-induced 
diabetes 
Values are represented as mean±SEM, n=6. Statistically analysis 
was done with Dunnett’s Multiple Comparison Test and p<0.05 
was considered to be statistically significant; b = vs diabetic 
control; c = vs 100 mg/kg dose; p<0.05 = *; p<0.01= ^; p<0.001= # 
 
Effect of NHME on lipids level in liver homogenates in strepto-
zotocin-induced diabetes 
In the present study, cholesterol and triglycerides levels were also 
estimated in tissues (liver), the results were represented in fig. 4. 
The level of lipids was increased in streptozotocin control as 
compared to normal control. After treatment with extract and 
standard drug decreased levels of cholesterol and triglycerides were 
seen. The cholesterol and triglyceride level were found statistically 
significantly in NHME 400 mg/kg groups as compared to 
streptozotocin-induced diabetic control group.  
 
 
Fig. 4: Effect of NHME on lipids level in liver homogenates in 
streptozotocin-induced diabetes 
Values are represented as mean±SEM, n=6. Statistically analysis 
was done with Dunnett’s Multiple Comparison Test and p<0.05 
was considered to be statistically significant; b = vs diabetic 
control; c = vs 100 mg/kg dose; p<0.05 = *; p<0.01= ^; p<0.001= # 
 
Effect of NHME on hemoglobin and Hb glycated in strepto-
zotocin-induced diabetes 
Hb level in diabetic control rats was significantly reduced as 
compared to normal control. There was found significant reduction 
in HbA1c (mg/dl) level in NHAE 400 mg/kg group as compared to 
diabetic control. However, a significant increase in Hb concentration 
was observed in diabetic rats treated with NHME 200 and 400 
mg/kg and NHAE 200 and 400 mg/kg, as compared to diabetic 
control (fig. 5). After 28 d of treatment, the mean HbA1c level was 
significantly decreased by NHME 400 mg/kg groups, as compared to 
diabetic control.  
 
 
Fig. 5: Effect of NHME on Hemoglobin and Hb glycated in 
streptozotocin-induced diabetes 
Values are represented as mean±SEM, n=6. Statistically, 
analysis was done with Dunnett’s Multiple Comparison Test and 
p<0.05 was considered to be statistically significant; b = vs 
diabetic control; p<0.05 = *; p<0.01= ^; p<0.001= # 
 
Histopathology of pancreas in streptozotocin-induced diabetes 
Normal control rat pancreas section showed pancreatic lobules 
separated by connective tissue septa. The pancreatic lobules 
consisted largely of the exocrine acini and their intralobular ducts. 
Most of the lobules showed small, round, light-staining islets of 
langerhans. The center of islet cells consisted of aggregates of small 
β-cells (70%) have basophilic granules, while the periphery 
comprised of large α-cells (25%) have eosinophilic granules. 
Intervening these cells have seen thin-walled capillaries. Diabetic 
control (streptozotocin) rat pancreas section showed pancreatic 
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lobules separated by connective tissue septa. Some of the lobules 
showed small, round, light-staining islets of langerhans. The center 
of islet cells consisted of a quantitative decrease in β-cells (40%) 
have basophilic granules, while the periphery comprised of large α-
cells (55%) have eosinophilic granules. Scattered lymphocytes 
within the islet cells were seen. Glibenclamide rat pancreas section 
showed pancreatic lobules separated by connective tissue septa. 
Most of the lobules showed large areas of light staining islets of 
langerhans. The center of islet cells consisted of a mild quantitative 
increase in β-cells (75%) have basophilic granules, while the 
periphery comprised of α-cells have eosinophilic granules. 
Congested vascular spaces amidst these cells were appeared. NHME 
400 mg/kg section showed pancreatic lobules separated by thin 
connective tissue septa. Most of the lobules showed very small areas 
of light staining islets of Langerhans. The center of islet cells 
consisted of a quantitative decrease in β-cells (50%) having 
basophilic granules, while the periphery comprised of α-cells (70%) 






Fig. 6: Histopathological images of pancreas in streptozotocin induced diabetes 
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Streptozotocin is a broad spectrum antibiotic extracted from 
streptomyces acromogenes. Like alloxan, streptozotocin causes 
hyperglycemia mainly by its direct cytotoxic action on the pancreatic 
beta cells. In streptozotocin, nitrosourea moiety is responsible for β-
cell toxicity, while deoxyglucose moiety facilitates transport across 
the cell membrane. Like alloxan, the involvement of free radical 
generation and resulting alteration of endogenous scavengers of 
these reactive species has been reported in streptozotocin-induced 
diabetes [26, 27].  
The body weight of streptozotocin-induced diabetic rats was 
reduced and also recovered after antidiabetic treatment [28]. In the 
present study, changes in body weights were found in extracts, and 
glibenclamide treated diabetic rats. The enhancement of body 
weight in streptozotocin-induced diabetic treated rats because of 
increase glucose metabolism. The treatment of streptozotocin-
induced diabetic rats with a plant extract that activated the β-cells 
and granulation return to normal like to be an insulinogenic effect 
[29]. The glibenclamide is a standard antidiabetic drug, used to 
compare the antidiabetic property in experimental rats. 
Glibenclamide has been involved in stimulating insulin secretion 
from pancreatic β-cells principally by inhibiting ATP-sensitive KATP 
channels in the plasma membrane [30]. Courtois et al., have 
reported that glibenclamide treated streptozotocin-induced diabetic 
rats showed a decrease in blood glucose level. The previous reports 
were consistent with our present findings [31]. The decreased level 
of blood glucose was observed in the present study, which indicates 
that extracts stimulated insulin secretion from the remnant β-cells 
or regenerated β-cells. The mechanism of the antidiabetic activity of 
extracts may be involved by increasing either the pancreatic 
secretion of insulin from the remnant Q cells of the islets of 
Langerhans. Some plants have antidiabetic activity through insulin 
releasing stimulatory effects [32].  
The excess glucose was present within the blood during diabetes, 
which reacts with hemoglobin and form glycosylated hemoglobin. 
The various proteins, including hemoglobin, albumin, collagen and 
low-density lipoprotein (LDL)/crystalline proteins undergo 
nonenzymatic glycation in diabetes [33]. The hemoglobin level was 
decreased in diabetic rats that may increase the formation of 
glycosylated hemoglobin. Glycosylated hemoglobin was found to be 
increased in diabetic mellitus, and a number of increases is directly 
proportional to that of fasting blood-glucose level. The significant 
decreased in glycosylated hemoglobin indicated that the efficiency of 
extracts in glycemic control [34].  
Lipid played an important role in the pathogenesis of complications 
associated with diabetes mellitus. The elevated level of serum 
cholesterol and reduced level of serum HDL cholesterol in diabetic 
condition poses to be a risk of the factor for developing 
microvascular complication leading to atherosclerosis and further 
cardiovascular diseases like coronary heart disease [35]. The 
abnormal high concentration of serum lipid in diabetic mainly due to 
increased mobilization of free fatty acids from peripheral fat depots, 
and insulin deficiency or insulin resistance may be responsible for 
dyslipidemia [36]. Whereas NHME treated showed significant 
improvement in the lipid profile as compared to diabetic control. 
Interestingly, 400 mg/kg of NHME produced significant attenuation 
in TC and TG levels as compared to diabetic control. In various 
studies, diabetic rats were found to be possessing high lipid level 
[37-39] and similar results were observed during the present study. 
The dyslipidemic conditions were improved in NHME 400 mg/kg 
groups as compared to diabetic control.  
Liver is the principal organ occupied with xenobiotic metabolisms, 
such as medicinal plant extracts and also a target tissue where 
possible toxicity effect of same is first expressed [40]. Therefore, in 
present study total cholesterol and total triglyceride levels were 
investigated in liver homogenates. Although products of lipid 
digestion are emptied directly into the blood via lymph as 
chylomicrons, chylomicrons travel through the blood stream to 
supply fatty acids to needed tissues, and their remnants are 
removed from the blood by the liver for recycling. The liver also 
recovers cholesterol from bile, synthesized more cholesterol and 
triacylglycerol from excess acetyl units of diets and processes them 
into transport forms-lipoproteins [41]. Moreover, many genetic and 
acquired disorders like diabetes, atherosclerosis, etc may lead to 
deposits of lipids in vital organs such as liver and kidney, resulting in 
their impaired function [42]. Consequently, assayed the most 
common lipid's total cholesterol and triglyceride usually implicated 
in diabetes in the hepatocytes of diabetic and non-diabetic rats, 
which received extract treatments. The result showed the decrease 
in cholesterol and triglyceride levels.  
It has been noted that abnormal lipid results, often lead to disturb 
normal architecture in the pancreas or other tissues [41]. So, ahead 
to histopathology of the pancreas that clearly indicated in the 
restoration of near normal architecture pancreatic islets of 
langerhans and hepatocytes in NHME 400 mg/kg and glibenclamide.  
CONCLUSION  
In the present study, the antidiabetic effect of methanolic extract of 
Nepeta hindostana whole herb in rats was evaluated. It was found 
that extract might be useful in diabetes, irrespective of whether the 
pancreas is partly functional or almost totally destroyed. The results 
clearly disclosed the glucose and lipid lowering potential of 
methanolic extract of Nepeta hindostana whole herb in 
streptozotocin-induced diabetes in the rat.  
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